Next Article in Journal
Stem Cell-Derived Exosomes Ameliorate Doxorubicin-Induced Muscle Toxicity through Counteracting Pyroptosis
Next Article in Special Issue
Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
Previous Article in Journal
A Critical Appraisal of New Developments in Intraocular Lens Modifications and Drug Delivery Systems for the Prevention of Cataract Surgery Complications
Previous Article in Special Issue
Iron Pathways and Iron Chelation Approaches in Viral, Microbial, and Fungal Infections

Iron Therapeutics in Women’s Health: Past, Present, and Future

Department of Academic Affairs, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33314, USA
Author to whom correspondence should be addressed.
These authors contributed equally to this paper.
Pharmaceuticals 2020, 13(12), 449;
Received: 4 October 2020 / Revised: 28 November 2020 / Accepted: 4 December 2020 / Published: 8 December 2020
(This article belongs to the Special Issue Iron as Therapeutic Targets in Human Diseases 2020)
Iron plays a unique physiological role in the maintenance of homeostasis and the pathological outcomes of the female reproductive tract. The dual nature of elemental iron has created an evolutionary need to tightly regulate its biological concentration. The female reproductive tract is particularly unique due to the constant cycle of endometrial growth and shedding, in addition to the potential need for iron transfer to a developing fetus. Here, iron regulation is explored in a number of physiologic states including the endometrial lining and placenta. While iron dysregulation is a common characteristic in many women’s health pathologies there is currently a lack of targeted therapeutic options. Traditional iron therapies, including iron replacement and chelation, are common treatment options for gynecological diseases but pose long term negative health consequences; therefore, more targeted interventions directed towards iron regulation have been proposed. Recent findings show potential benefits in a therapeutic focus on ferritin-hepcidin regulation, modulation of reactive oxygen species (ROS), and iron mediated cell death (ferroptosis). These novel therapeutics are the direct result of previous research in iron’s complex signaling pathway and show promise for improved therapy, diagnosis, and prognosis in women’s health. View Full-Text
Keywords: oxidative stress; carcinogenesis; mini-hepcidin; iron therapeutics oxidative stress; carcinogenesis; mini-hepcidin; iron therapeutics
Show Figures

Figure 1

MDPI and ACS Style

Mintz, J.; Mirza, J.; Young, E.; Bauckman, K. Iron Therapeutics in Women’s Health: Past, Present, and Future. Pharmaceuticals 2020, 13, 449.

AMA Style

Mintz J, Mirza J, Young E, Bauckman K. Iron Therapeutics in Women’s Health: Past, Present, and Future. Pharmaceuticals. 2020; 13(12):449.

Chicago/Turabian Style

Mintz, Joel, Jackie Mirza, Eric Young, and Kyle Bauckman. 2020. "Iron Therapeutics in Women’s Health: Past, Present, and Future" Pharmaceuticals 13, no. 12: 449.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop